353 related articles for article (PubMed ID: 25785551)
41. [A Newly Diagnosed Case of Multiple Myeloma in Which Lenalidomide Was Continued after Surgery for a Pancreatic Neuroendocrine Tumor That Developed during Lenalidomide Maintenance Therapy].
Kuroda H; Yoshida M; Usami M; Shimoyama S; Sakamoto H; Yamada M; Fujii S; Maeda M; Fujita M; Kanari Y; Sato T; Kato J
Gan To Kagaku Ryoho; 2015 Aug; 42(8):1009-12. PubMed ID: 26321720
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Pelligra CG; Parikh K; Guo S; Chandler C; Mouro J; Abouzaid S; Ailawadhi S
Clin Ther; 2017 Oct; 39(10):1986-2005.e5. PubMed ID: 28967482
[TBL] [Abstract][Full Text] [Related]
43. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
Scott LJ; Lyseng-Williamson KA
BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
[TBL] [Abstract][Full Text] [Related]
44. Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.
Zhou DB; Yu L; Du X; Jin J; Cai Z; Chen F; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; DeMarco D; Chen N; Mei J; Wang J; Hou J
Int J Hematol; 2015 Jun; 101(6):569-77. PubMed ID: 25753225
[TBL] [Abstract][Full Text] [Related]
45. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Hornberger J; Rickert J; Dhawan R; Liwing J; Aschan J; Löthgren M
Eur J Haematol; 2010 Dec; 85(6):484-91. PubMed ID: 20846301
[TBL] [Abstract][Full Text] [Related]
46. Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan.
Liu Y; Tang CH; Qiu H; Siggins S; Hou HA
Sci Rep; 2021 Jan; 11(1):1112. PubMed ID: 33441901
[TBL] [Abstract][Full Text] [Related]
47. Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
Antunes L; Rocha-Gonçalves F; Chacim S; Lefèvre C; Pereira M; Pereira S; Zagorska A; Bento MJ
Eur J Cancer Care (Engl); 2019 Jul; 28(4):e13026. PubMed ID: 30828907
[TBL] [Abstract][Full Text] [Related]
48. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
[TBL] [Abstract][Full Text] [Related]
49. Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco-economic assessment.
Uyl-de Groot CA; Ramsden R; Lee D; Boersma J; Zweegman S; Dhanasiri S
Eur J Haematol; 2020 Nov; 105(5):635-645. PubMed ID: 32705720
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
[TBL] [Abstract][Full Text] [Related]
51. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.
Dimopoulos MA; Palumbo A; Attal M; Beksaç M; Davies FE; Delforge M; Einsele H; Hajek R; Harousseau JL; da Costa FL; Ludwig H; Mellqvist UH; Morgan GJ; San-Miguel JF; Zweegman S; Sonneveld P;
Leukemia; 2011 May; 25(5):749-60. PubMed ID: 21293488
[TBL] [Abstract][Full Text] [Related]
52. Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Terpos E; Migkou M; Christoulas D; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Iakovaki M; Panagiotidis I; Ziogas DC; Fotiou D; Kastritis E; Dimopoulos MA
Blood Cancer J; 2016 May; 6(5):e428. PubMed ID: 27232930
[TBL] [Abstract][Full Text] [Related]
53. Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
Offidani M; Corvatta L; Bringhen S; Gentili S; Troia R; Maracci L; Larocca A; Gay F; Leoni P; Boccadoro M
Eur J Haematol; 2017 Mar; 98(3):289-295. PubMed ID: 27893171
[TBL] [Abstract][Full Text] [Related]
54. A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.
Lee C; Grigorian M; Nolan R; Binder G; Rice G
J Med Econ; 2016; 19(4):397-402. PubMed ID: 26652728
[TBL] [Abstract][Full Text] [Related]
55. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
56. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
57. Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy.
Emond B; Sundaram M; Romdhani H; Lefebvre P; Wang S; Mato A
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):763-775.e2. PubMed ID: 31678080
[TBL] [Abstract][Full Text] [Related]
58. Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Pantani L; Zamagni E; Zannetti BA; Pezzi A; Tacchetti P; Brioli A; Mancuso K; Perrone G; Rocchi S; Tosi P; Cavo M
Ann Hematol; 2014 Jan; 93(1):123-8. PubMed ID: 23864035
[TBL] [Abstract][Full Text] [Related]
59. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.
Montefusco V; Galli M; Spina F; Stefanoni P; Mussetti A; Perrone G; De Philippis C; Dalto S; Maura F; Bonini C; Rezzonico F; Pennisi M; Roncari L; Soldarini M; Dodero A; Farina L; Cocito F; Caprioli C; Corradini P
Leuk Lymphoma; 2014 Sep; 55(9):2032-7. PubMed ID: 24730540
[TBL] [Abstract][Full Text] [Related]
60. Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience.
Zhou X; Xia J; Mao J; Cheng F; Qian X; Guo H
Hematology; 2016 Jun; 21(5):280-6. PubMed ID: 26900623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]